A-shares open · 港股交易中 Quotes 行情 · 28 Sep 09:34 CST
28 Sep 2026 · 09:34 CST Terminal Access 终端入口 →
600332.SH上海证券交易所 · 主板 Main

Guangzhou Baiyunshan Pharmaceutical Holdings 白云山

Traditional Chinese Medicine 中药Ⅱ
¥19.43+¥0.04 · +0.21%Live 实时 · 28 Sep 2026 · 09:34 CST · CNY
Open 开盘
¥19.38
High 最高
¥19.55
Low 最低
¥19.38
Prev Close 昨收
¥19.39
Volume 成交量
46.0万股
Turnover 成交额
¥894.4万
Mkt Cap 总市值
¥316亿
P/E 市盈率
12.3×
Recent Activity 近期动态All Filings 全部公告 →

5 significant filings since 31 May 2026: 1 on change of control, 3 on dividend and 1 on legal representative change. The latest, on 22 Sep 2026: 广州白云山医药集团股份有限公司关于控股股东股权结构变更的提示性公告.
自 31 May 2026 起有 5 份重大公告:change of control 1 份、dividend 3 份、legal representative change 1 份。最新一份(22 Sep 2026):广州白云山医药集团股份有限公司关于控股股东股权结构变更的提示性公告。

Price History 价格走势

22 trading days 个交易日 · High 最高 ¥20.17 · Low 最低 ¥19.39
19.4019.6019.8020.00
Volume 成交量
1,001.4万
26 Aug02 Sep09 Sep17 Sep24 Sep

Against Its Own History 与自身历史比较

12.3×
Median 中值 13.1× · Range 区间 10.9× to 16.3× · 20 periods 期
0.81×
Median 中值 1.34× · Range 区间 0.83× to 1.91× · 20 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥20.04¥1.5812.7×¥24.070.83×
31 Mar 2026 一季报¥22.86¥1.8112.6×¥24.330.94×
31 Dec 2025 年报¥25.74¥1.8314.0×¥23.241.11×
30 Sep 2025 三季报¥25.55¥1.8413.9×¥23.321.10×
30 Jun 2025 中报¥26.36¥1.7215.3×¥23.231.13×
31 Mar 2025 一季报¥26.46¥1.6615.9×¥23.201.14×
31 Dec 2024 年报¥28.42¥1.7416.3×¥22.081.29×
30 Sep 2024 三季报¥30.66¥2.1114.6×¥22.281.38×
30 Jun 2024 中报¥29.33¥2.3312.6×¥22.311.31×
31 Mar 2024 一季报¥28.85¥2.5211.4×¥22.681.27×
31 Dec 2023 年报¥28.60¥2.5011.5×¥21.481.33×
30 Sep 2023 三季报¥31.42¥2.6411.9×¥21.321.47×
30 Jun 2023 中报¥31.88¥2.5812.4×¥20.721.54×
31 Mar 2023 一季报¥33.08¥2.5013.2×¥20.891.58×
31 Dec 2022 年报¥29.79¥2.4412.2×¥19.721.51×
30 Sep 2022 三季报¥25.96¥2.3910.9×¥19.331.34×
30 Jun 2022 中报¥31.59¥2.3413.5×¥18.791.68×
31 Mar 2022 一季报¥31.36¥2.4013.1×¥18.991.65×
31 Dec 2021 年报¥34.20¥2.2914.9×¥17.881.91×
30 Sep 2021 三季报¥29.77¥2.1913.6×¥17.581.69×

Consensus Forward EPS 机构预测每股收益

No broker forecasts for this company yet 暂无机构预测

Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA